Background

Dr Sherrie Kelly is an infectious disease modeller specialising in applied health economics. She has over 15 years of experience working with countries across all income levels and global regions, as well as with a wide range of national and international organisations.

Dr Kelly has a background in epidemiology and global health with focus on HIV, TB, and maternal-child health. Dr Kelly leads the Burnet Institute’s Optima group on HIV, TB, and malaria modeling applications and research, as well as facilitates Optima training workshops and country missions.

Prior to joining the Optima team, Dr Kelly worked with UNAIDS and the Public Health Agency of Canada, having experience in infectious disease emergency response and basic laboratory research.

Appointments

• HIV Modelling Consortium – Participant, 2016
• International AIDS Society - Member

Positions

• Research Associate, Burnet Institute, Melbourne, Australia, 2015 to present
• Epidemiologist, Children’s Hospital of Eastern Ontario, Ottawa, Canada 2011–2014
• Epidemiologist, HIV/AIDS Surveillance Section, Public Health Agency of Canada, Ottawa, Canada, 2011 and 2013
• Epidemiological Data Analyst, UNAIDS, Geneva, Switzerland (remote part-time contractor 2009-2012), 2007–2012
• Data Analyst, Manitoba Public Health, Tuberculosis Control Program, Winnipeg, Canada, 2006–2007
• Project Administrator, National Food Institute, Copenhagen, Denmark, 2005–2006
• Bioinformatician, Public Health Agency of Canada, Winnipeg, Canada, 2002–2005
• Research Assistant/Student, University of Toronto (2002), University of Manitoba (1996–2001)

Qualifications

• PhD, Infectious Disease Modelling, Monash University, Australia, 2014–2017
• MSc, Biochemistry and Medical Genetics, University of Manitoba, 1999–2001
• BSc, Genetics Honours, 1st Class, University of Manitoba, 1994–1998

Awards

• Sexual Health Society of Victoria (SHSOV) Educational Support Grant ($1,000) - 2016
• Monash Graduate International Postgraduate Research Scholarship ($26,288/year, 3 years) - 2016–17
• University International Postgraduate Award, UNSW Australia ($25,392/year, 3 years) - 2014–16
• SARS Outbreak Special Team Excellence Award, National Microbiology Laboratory, PHAC - 2003
• Manitoba Health Research Council Studentship ($17,900/year, 2 years) - 1998–01
• Phyllis J McAlpine Graduate Fellowship, University of Manitoba ($500) - 2000–01
• Manitoba Medical Service Foundation Poster Competition Award for Excellence ($200) - 2000
• Alumni Association Travel Award, University of Manitoba ($500) - 2000
• Biochemistry and Medical Genetics Travel Award, University of Manitoba ($500) - 2000
• First Class Honours Award for Bachelor of Science Genetics Degree, University of Manitoba - 1998
• Bachelor of Science Dean’s Honours List, University of Manitoba - 1997–98

Projects (1)

Current (1)

• 

  Decision science using Optima

Publications (33)

2022 (1)

• Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis.
  Ward Z, Stone J, Bishop C, Ivakin V, Eritsyan K, Deryabina A, Low A, Cepeda J, Kelly SL, Heimer R, Cook R, Altice FL, Litz T, Terlikbayeva A, El-Bassel N, Havarkov D, Fisenka A, Boshnakova A, Klepikov A, Saliuk T, Deshko T, Vickerman P
  Lancet HIV. 2022 Jan; 9(1):e42-e53

2021 (5)

• The risks and benefits of providing HIV services during the COVID-19 pandemic.
  Stover J, Kelly SL, Mudimu E, Green D, Smith T, Taramusi I, Bansi-Matharu L, Martin-Hughes R, Phillips AN, Bershteyn A
  PLoS One. 2021 Dec; 16(12):e0260820
• Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland.
  Shattock AJ, Le Rutte EA, Robert P Dünner RP, Sen S, Kelly SL, Chitnis N, Penny MA
  Epidemics. 2021 Dec; 38:100535
• Modeling the epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030.
  Stover J, Glaubius R, Teng Y, Kelly S, Brown T, Hallett TB, Revill P, Bärnighausen T, Phillips AN, Fontaine C, Frescura L, Izazola-Licea JA, Semini I, Godfrey-Faussett P, De Lay PR, Benzaken AS, Ghys PD
  PLoS Med. 2021 Oct; 18(10):e1003831
• Optima TB: A tool to help optimally allocate tuberculosis spending.
  Goscé L, Abou Jaoude GJ, Kedziora DJ, Benedikt C, Hussain A, Jarvis S, Skrahina A, Klimuk D, Hurevich H, Zhao F, Fraser-Hurt N, Cheikh N, Gorgens M, Wilson DJ, Abeysuriya R, Martin-Hughes R, Kelly SL, Roberts A, Stuart RM, Palmer T, Panovska-Griffiths J, Kerr CC, Wilson DP, Haghparast-Bidgoli H, Skordis J, Abubakar I.
  PLoS Comput Biol. 2021 Sep; 17(9):e1009255
• Covasim: An agent-based model of COVID-19 dynamics and interventions.
  Kerr CC, Stuart RM, Mistry D, Abeysuriya RG, Rosenfeld K, Hart GR, Núñez RC, Cohen JA, Selvaraj P, Hagedorn B, George L, Jastrzębski M, Izzo AS, Fowler G, Palmer A, Delport D, Scott N, Kelly SL, Bennette CS, Wagner BG, Chang ST, Oron AP, Wenger EA, Panovska-Griffiths J, Famulare M, Klein DJ
  PLoS Comput Biol. 2021 Jul; 17(7):e1009149

2020 (5)

• Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.
  Jewell BL, Mudimu E, Stover J, Ten Brink D, Phillips AN, Smith JA, Martin-Hughes R, Teng Y, Glaubius R, Mahiane SG, Bansi-Matharu L, Taramusi I, Chagoma N, Morrison M, Doherty M, Marsh K, Bershteyn A, Hallett TB, Kelly SL; HIV Modelling Consortium
  Lancet HIV. 2020 Aug; 7(9):e929-e940
• Opportunities for improved HIV prevention and treatment through budget optimization in Eswatini.
  Minnery M, Mathabela N, Shubber Z, Mabuza K, Gorgens M, Cheikh N, Wilson DP, Kelly SL
  PLoS One. 2020 Jul; 15(7):e0235664
• Integrating HIV pre-exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study.
  Bórquez A, Rich K, Farrell M, Degenhardt L, McKetin R, Tran LT, Cepeda J, Silva-Santisteban A, Konda K, Cáceres CF, Kelly S, Altice FL, Martin NK
  J Int AIDS Soc. 2020 Jun; 23 Suppl 1:e25495
• Potential health gains among key populations in West and Central Africa through savings from lower-cost HIV treatment.
  Stuart RM, Kelly SL, Martin-Hughes R, Wilson DP
  AIDS. 2020 Mar; 34(3):439-446
• Modelling the impact of migrants on the success of the HIV care and treatment program in Botswana.
  Marukutira T, Scott N, Kelly SL, Birungi C, Makhema JM, Crowe S, Stoové M, Hellard M
  PLoS One. 2020 Jan; 15(1):e0226422

2019 (4)

• The influence of constraints on the efficient allocation of resources for HIV prevention.
  Stuart RM, Kelly SL, Kerr CC, Martin-Hughes R, Wilson DP
  AIDS. 2019 Oct; 33(12):1949-1950
• What is the impact of a 20% funding cut in international HIV aid from the United States?
  Ten Brink D, Martin-Hughes R, Kelly SL, Wilson DP
  AIDS. 2019 Jul; 33(8):1406-1408
• Applying the 'no-one worse off' criterion to design Pareto efficient HIV responses in Sudan and Togo.
  Stuart RM, Haghparast-Bidgoli H, Panovska-Griffiths J, Grobicki L, Skordis J, Kerr CC, Kedziora DJ, Martin-Hughes R, Kelly SL, Wilson DP
  AIDS. 2019 Jun; 33(7):1247-1252
• The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
  Bórquez A, Guanira JV, Revill P, Caballero P, Silva-Santisteban A, Kelly S, Salazar X, Bracamonte P, Minaya P, Hallett TB, Cáceres CF
  Lancet Public Health. 2019 Jan; 4(3):e127-e136

2018 (5)

• "Optima attempts to objectively and pragmatically assist countries meet their targets most efficiently and effectively".
  Wilson DP, Gorgens M, Wilson DJ; Optima HIV study team (including: Robyn M Stuart, Cliff C Kerr, Jolene Skordis, Olivia Keiser, Sherrie Kelly, Rowan Martin-Hughes, Janka Petravic, Richard Gray and Nejma Cheikh)
  J Int AIDS Soc. 2018 Oct; 21(10):e25190
• How should HIV resources be allocated? Lessons learnt from applying Optima HIV in 23 countries.
  Stuart RM, Grobicki L, Haghparast-Bidgoli H, Panovska-Griffiths J, Skordis J, Keiser O, Estill J, Baranczuk Z, Kelly SL, Reporter I, Kedziora DJ, Shattock AJ, Petravic J, Hussain SA, Grantham KL, Gray RT, Yap XF, Martin-Hughes R, Benedikt CJ, Fraser-Hurt N, Masaki E, Wilson DJ, Gorgens M, Mziray E, Cheikh N, Shubber Z, Kerr CC, Wilson DP
  J Int AIDS Soc. 2018 Apr; 21(4):e25097
• Achieving 90-90-90 HIV targets will not be enough to achieve the HIV incidence reduction target in Australia.
  Scott N, Stoové M, Kelly SL, Wilson DP, Hellard ME
  Clin Infect Dis. 2018 Mar; 66(7):1019-1023
• The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS.
  Kelly SL, Martin-Hughes R, Stuart RM, Yap XF, Kedziora DJ, Grantham KL, Hussain SA, Reporter I, Shattock AJ, Grobicki L, Haghparast-Bidgoli H, Skordis-Worrall J, Baranczuk Z, Keiser O, Estill J, Petravic J, Gray RT, Benedikt CJ, Fraser N, Gorgens M, Wilson D, Kerr CC, Wilson DP
  Lancet HIV. 2018 Mar; 5(4):e190-e198
• A tale of two countries: progress towards UNAIDS 90-90-90 targets in Botswana and Australia.
  Marukutira T, Stoové M, Lockman S, Mills LA, Gaolathe T, Lebelonyane R, Jarvis JN, Kelly SL, Wilson DP, Luchters S, Crowe SM, Hellard M
  J Int AIDS Soc. 2018 Mar; 21(3):e25090

2017 (2)

• Getting it right when budgets are tight: Using optimal expansion pathways to prioritize responses to concentrated and mixed HIV epidemics.
  Stuart RM, Kerr CC, Haghparast-Bidgoli H, Estill J, Grobicki L, Baranczuk Z, Prieto L, Montañez V, Reporter I, Gray RT, Skordis-Worrall J, Keiser O, Cheikh N, Boonto K, Osornprasop S, Lavadenz F, Benedikt CJ, Martin-Hughes R, Hussain SA, Kelly SL, Kedziora DJ, Wilson DP
  PLoS One. 2017 Oct; 12(10):e0185077
• Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies.
  Shattock AJ, Benedikt C, Bokazhanova A, Đurić P, Petrenko I, Ganina L, Kelly SL, Stuart RM, Kerr CC, Vinichenko T, Zhang S, Hamelmann C, Manova M, Masaki E, Wilson DP, Gray RT
  PLoS One. 2017 Feb; 12(2):e0169530

2016 (2)

• GBD 2015 and HIV estimates from the Optima model.
  Kelly SL, Wilson DP
  Lancet HIV. 2016 Dec; 3(12):e558
• Optimizing HIV/AIDS resources in Armenia: increasing ART investment and examining HIV programmes for seasonal migrant labourers.
  Kelly SL, Shattock AJ, Kerr CC, Stuart RM, Papoyan A, Grigoryan T, Hovhannisyan R, Grigoryan S, Benedikt C, Wilson DP
  J Int AIDS Soc. 2016 Jun; 19(1):20772

2015 (2)

• HIV Cascade Monitoring and Simple Modeling Reveal Potential for Reductions in HIV Incidence.
  Sherrie L Kelly, David P Wilson
  J Acquir Immune Defic Syndr. 2015 Jul; 69(3):257-263
• Factors Associated With Increased Rates of Caesarean Section in Women of Advanced Maternal Age.
  Ghayath Janoudi, Sherrie Kelly, Abdool Yasseen, Heba Hamam, Felipe Moretti, Mark Walker
  J Obstet Gynaecol Can. 2015 Jun; 37(6):517-526

2014 (1)

• HIV Mathematical Modelling to Support Swaziland's Development of its HIV Investment Case.
  Kelly S, Shattock A, Kerr CC, Gama T, Nhlabatsi N, Zagatti G, Harimurti P, Wilson DP, Gorgens M
  Report to the World Bank. 2014 Oct

2013 (2)

• Examining caesarean section rates in Canada using the Robson classification system.
  Sherrie Kelly, Ann Sprague, Deshayne B Fell, Phil Murphy, Nancy Aelicks, Yanfang Guo, John Fahey, Leeanne Lauzon, Heather Scott, Lily Lee, Brooke Kinniburgh, Monica Prince, Mark Walker
  J Obstet Gynaecol Can. 2013 Mar; 35(3):206-214
• Measuring quality in maternal-newborn care: developing a clinical dashboard.
  Ann E Sprague, Sandra I Dunn, Deshayne B Fell, Joann Harrold, Mark C Walker, Sherrie Kelly, Graeme N Smith
  J Obstet Gynaecol Can. 2013 Jan; 35(1):29-38

2008 (1)

• Estimates of HIV burden in emergencies.
  M Lowicki-Zucca, P B Spiegel, S Kelly, K-L Dehne, N Walker, P D Ghys
  Sex Transm Infect. 2008 Aug; 84 Suppl 1:i42-i48

2002 (1)

• HNF-1alpha G319S, a transactivation-deficient mutant, is associated with altered dynamics of diabetes onset in an Oji-Cree community.
  Barbara L Triggs-Raine, Robert D Kirkpatrick, Sherrie L Kelly, Lisa D Norquay, Peter A Cattini, Kazuya Yamagata, Anthony J G Hanley, Bernard Zinman, Stewart B Harris, P Hugh Barrett, Robert A Hegele
  Proc Natl Acad Sci U S A. 2002 Apr; 99(7):4614-4619

1999 (1)

• N-Acetylsphingosine stimulates phosphatidylglycerolphosphate synthase activity in H9c2 cardiac cells.
  F Y Xu, S L Kelly, G M Hatch
  Biochem J. 1999 Feb; 337 ( Pt 3):483-490

1998 (1)

• On the mechanism of the phospholipase C-mediated attenuation of cardiolipin biosynthesis in H9c2 cardiac myoblast cells.
  F Y Xu, S L Kelly, W A Taylor, G M Hatch
  Mol Cell Biochem. 1998 Nov; 188(1-2):217-223

News Articles (1)

2019 (1)

• Burnet at IAS 2019